5-(2-Dichloromethyl-4,5,5-trimethyl-[1,3,2]dioxaborolan-4-yl)-3-methyl-pentanoic acid tert-butyl ester | 208521-47-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 5-(2-Dichloromethyl-4,5,5-trimethyl-[1,3,2]dioxaborolan-4-yl)-3-methyl-pentanoic acid tert-butyl ester
• 英文别名: Tert-butyl 5-[2-(dichloromethyl)-4(rs),5,5-trimethyl-1,3,2-dioxaborolan-4-yl]-3(rs)-methylvalerate；tert-butyl 5-[2-(dichloromethyl)-4,5,5-trimethyl-1,3,2-dioxaborolan-4-yl]-3-methylpentanoate
• CAS: 208521-47-5
• 化学式: C₁₆H₂₉BCl₂O₄
• 分子量: 367.121
• InChiKey: HDERJPWLUDNHJM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.55
• 重原子数：
  23
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  44.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-(2-Dichloromethyl-4,5,5-trimethyl-[1,3,2]dioxaborolan-4-yl)-3-methyl-pentanoic acid tert-butyl ester 以 四氢呋喃 、 乙醚 为溶剂， 生成 5-[2-(1-Amino-propyl)-4,5,5-trimethyl-[1,3,2]dioxaborolan-4-yl]-3-methyl-pentanoic acid tert-butyl ester; compound with trifluoro-acetic acid
  参考文献：
  名称：

  Solid phase synthesis of aminoboronic acids: potent inhibitors of the hepatitis C virus NS3 proteinase

  摘要：

  Use of a resin bound diol as a boronic acid protecting group has been developed to allow the parallel synthesis of potent inhibitors of the hepatitis C virus NS3 serine proteinase. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00284-5
• 作为产物：
  描述：

  tert-butyl 3(RS),7-dimethyl-6-octenoate 在 potassium permanganate 、 溶剂黄146 作用下， 以 四氢呋喃 、 乙醚 、 丙酮 为溶剂， 生成 5-(2-Dichloromethyl-4,5,5-trimethyl-[1,3,2]dioxaborolan-4-yl)-3-methyl-pentanoic acid tert-butyl ester
  参考文献：
  名称：

  Solid phase synthesis of aminoboronic acids: potent inhibitors of the hepatitis C virus NS3 proteinase

  摘要：

  Use of a resin bound diol as a boronic acid protecting group has been developed to allow the parallel synthesis of potent inhibitors of the hepatitis C virus NS3 serine proteinase. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00284-5

文献信息

• Peptidyl inhibitors of viral proteases
  申请人：Hoffmann-La Roche Inc.

  公开号：US05866684A1

  公开（公告）日：1999-02-02

  The invention provides amino acid derivatives of the formula ##STR1## wherein E represents CHO or B(OH).sub.2 ; R.sup.1 represents lower alkyl (optionally substituted by halo, cyano, lower alkylthio, aryl-lower alkylthio, aryl or heteroaryl), lower alkenyl or lower alkynyl; R.sup.2 represents lower alkyl optionally substituted by hydroxy, carboxy, aryl, aminocarbonyl or lower cycloalkyl; and R.sup.3 represents hydrogen or lower alkyl; or R.sup.2 and R.sup.3 together represent di- or trimethylene optionally substituted by hydroxy; R.sup.4 represents lower alkyl (optionally substituted by hydroxy, lower cycloalkyl, carboxy, aryl, lower alkylthio, cyano-lower alkylthio or aryl-lower alkylthio), lower alkenyl, aryl or lower cycloalkyl; R.sup.5 represents lower alkyl (optionally substituted by hydroxy, lower alkylthio, aryl, aryl-lower alkylthio or cyano-lower alkylthio) or lower cycloalkyl; R.sup.6 represents hydrogen or lower alkyl; R.sup.7 represent lower alkyl (optionally substituted by hydroxy, carboxy, aryl or lower cycloalkyl) or lower cycloalkyl; R.sup.8 represents lower alkyl optionally substituted by hydroxy, carboxy or aryl; and R.sup.9 represents lower alkylcarbonyl, carboxy-lower alkylcarbonyl, arylcarbonyl, lower alkylsulphonyl, arylsulphonyl, lower alkoxycarbonyl or aryl-lower al koxycarbonyl, and salts of acidic compounds of formula I with bases, which are viral proteinase inhibitors useful as antiviral agents, especially for the treatment or prophylaxis of infections caused by Hepatitis C, Hepatitis G and human GB viruses.

  本发明提供了式子为##STR1##的氨基酸衍生物，其中E代表CHO或B(OH).sub.2；R.sup.1代表较低的烷基（可选择地被卤素、氰基、较低的烷基硫、芳基-较低的烷基硫、芳基或杂环芳基取代）、较低的烯基或较低的炔基；R.sup.2代表较低的烷基，可选择地被羟基、羧基、芳基、氨基甲酰或较低的环烷基取代；R.sup.3代表氢或较低的烷基；或者R.sup.2和R.sup.3一起代表二甲基或三甲基，可选择地被羟基取代；R.sup.4代表较低的烷基（可选择地被羟基、较低的环烷基、羧基、芳基、较低的烷基硫、氰基-较低的烷基硫或芳基-较低的烷基硫取代）、较低的烯基、芳基或较低的环烷基；R.sup.5代表较低的烷基（可选择地被羟基、较低的烷基硫、芳基、芳基-较低的烷基硫或氰基-较低的烷基硫取代）或较低的环烷基；R.sup.6代表氢或较低的烷基；R.sup.7代表较低的烷基（可选择地被羟基、羧基、芳基或较低的环烷基取代）或较低的环烷基；R.sup.8代表较低的烷基，可选择地被羟基、羧基或芳基取代；R.sup.9代表较低的烷基羰基、羧基-较低的烷基羰基、芳基羰基、较低的烷基磺酰基、芳基磺酰基、较低的烷氧羰基或芳基-较低的烷氧羰基；以及式I的酸性化合物与碱的盐，它们是病毒蛋白酶抑制剂，特别是用于治疗或预防由丙型肝炎、丙型肝炎G和人类GB病毒引起的感染的抗病毒药物。
• Antiviral medicaments
  申请人：Hoffmann-La Roche Inc.

  公开号：US06372883B1

  公开（公告）日：2002-04-16

  The invention is concerned with amino acid derivatives of the formula and salts of acidic compounds of formula I with bases, which are viral proteinase inhibitors useful as antiviral agents, especially for the treatment or prophylaxis of infections caused by Hepatitis C, Hepatitis G and human GB viruses.

  这项发明涉及公式I的氨基酸衍生物和酸性化合物的盐与碱的化合物，这些化合物是病毒蛋白酶抑制剂，可用作抗病毒剂，特别是用于治疗或预防由丙型肝炎病毒、G型肝炎病毒和人类GB病毒引起的感染。
• US06018020
  申请人：——

  公开号：——

  公开（公告）日：——
• Solid phase synthesis of aminoboronic acids: potent inhibitors of the hepatitis C virus NS3 proteinase
  作者：Rachel M Dunsdon、John R Greening、Philip S Jones、Steven Jordan、Francis X Wilson

  DOI：10.1016/s0960-894x(00)00284-5

  日期：2000.7

  Use of a resin bound diol as a boronic acid protecting group has been developed to allow the parallel synthesis of potent inhibitors of the hepatitis C virus NS3 serine proteinase. (C) 2000 Elsevier Science Ltd. All rights reserved.